Ocular Therapeutix Inc OCUL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $10.23
- Day Range
- $9.91–10.14
- 52-Week Range
- $6.24–16.41
- Bid/Ask
- $9.87 / $9.94
- Shares Outstanding
- 219.62M
- Market Cap
- $2.22B
- Volume/Avg
- 1,423 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 41.52
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 325
- Website
- https://www.ocutx.com
Valuation
|
Metric
|
OCUL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.26 |
Price/Sales | 41.52 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OCUL
|
|---|---|
Quick Ratio | 12.79 |
Current Ratio | 13.11 |
Interest Coverage | −27.42 |
Quick Ratio
OCUL
Profitability
|
Metric
|
OCUL
|
|---|---|
Return on Assets (Normalized) | −39.78% |
Return on Equity (Normalized) | −52.71% |
Return on Invested Capital (Normalized) | −47.19% |
Return on Assets
OCUL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|vlz@cH | LOCK|%NWD | $131B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|SLWb?j | LOCK|%&@z^ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|BH$&Dn | LOCK|P& | $54B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|WWjb!%l | LOCK|#y@q | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Kc@tFRX | LOCK|j?? | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|PNSW<g | LOCK|nqWF^ | $30B | |||
| Moderna Inc
MRNA
| LOCK|V#G$P! | LOCK|MS% | $25B | |||
| Incyte Corp
INCY
| LOCK|@dWp&$H | LOCK|^P | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|GHkF$<? | LOCK|!%q | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%@jCJ<G | LOCK|<@ | $16B |
United States